Summary
Cencora, Inc. (formerly AmerisourceBergen Corporation) issued an 8-K filing on December 15, 2009, detailing positive financial outlook updates provided at its annual Investor Day Meeting. The company announced expectations for its fiscal first quarter ending December 31, 2009, to exceed current analyst consensus for diluted earnings per share (EPS), projecting results several cents above the $0.43 consensus. This upward revision is attributed to robust revenue growth exceeding 10% for the quarter and contributions from generic pharmaceutical sales. Furthermore, Cencora raised its fiscal year 2010 guidance, anticipating diluted EPS to land at the higher end of its previously communicated range of $1.82 to $1.92 per share. These announcements suggest strong operational performance and a positive trajectory for the company heading into the next fiscal year. Investors should note the included exhibits for a full understanding of the presented materials.
Key Highlights
- 1Cencora (formerly AmerisourceBergen) announced an Investor Day Meeting on December 15, 2009.
- 2The company expects Q1 FY2010 diluted EPS to be above the consensus of $0.43.
- 3Key drivers for the Q1 EPS beat include revenue growth exceeding 10% and generic pharmaceutical sales.
- 4Cencora anticipates Q1 FY2010 revenue growth to be over 10%.
- 5Fiscal Year 2010 diluted EPS guidance has been revised upwards to the higher end of the $1.82-$1.92 range.
- 6The filing includes a press release (Exhibit 99.1) and investor presentation slides (Exhibit 99.2) as supporting documents.